vs

Side-by-side financial comparison of NorthEast Community Bancorp, Inc. (NECB) and Xilio Therapeutics, Inc. (XLO). Click either name above to swap in a different company.

NorthEast Community Bancorp, Inc. is the larger business by last-quarter revenue ($26.4M vs $13.7M, roughly 1.9× Xilio Therapeutics, Inc.). Xilio Therapeutics, Inc. runs the higher net margin — 75.7% vs 40.9%, a 34.8% gap on every dollar of revenue. NorthEast Community Bancorp, Inc. produced more free cash flow last quarter ($50.8M vs $-2.1M).

NorthEast Community Bancorp, Inc. (MD) is a U.S.-based bank holding company operating primarily in the Mid-Atlantic region. It provides a comprehensive suite of consumer and commercial banking services, including deposit products, mortgage loans, small business financing, and wealth management solutions to individual and local enterprise clients.

Xilio Therapeutics is a clinical-stage biotechnology company dedicated to developing novel tumor-selective immunotherapies for cancer treatment. Its product pipeline features candidates engineered to trigger anti-tumor immune responses specifically inside tumor microenvironments, reducing systemic toxicities, and it primarily targets oncology patient populations in North America and other global markets.

NECB vs XLO — Head-to-Head

Bigger by revenue
NECB
NECB
1.9× larger
NECB
$26.4M
$13.7M
XLO
Higher net margin
XLO
XLO
34.8% more per $
XLO
75.7%
40.9%
NECB
More free cash flow
NECB
NECB
$52.9M more FCF
NECB
$50.8M
$-2.1M
XLO

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
NECB
NECB
XLO
XLO
Revenue
$26.4M
$13.7M
Net Profit
$10.8M
$10.4M
Gross Margin
Operating Margin
59.0%
-86.5%
Net Margin
40.9%
75.7%
Revenue YoY
3.9%
Net Profit YoY
5.8%
179.1%
EPS (diluted)
$0.78
$-3.74

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
NECB
NECB
XLO
XLO
Q4 25
$26.4M
$13.7M
Q3 25
$27.0M
$19.1M
Q2 25
$25.9M
$8.1M
Q1 25
$25.5M
$2.9M
Q4 24
$25.4M
Q3 24
$27.6M
Q2 24
$27.0M
Q1 24
$25.5M
Net Profit
NECB
NECB
XLO
XLO
Q4 25
$10.8M
$10.4M
Q3 25
$11.9M
$-16.3M
Q2 25
$11.2M
$-15.8M
Q1 25
$10.6M
$-13.3M
Q4 24
$10.2M
Q3 24
$12.7M
Q2 24
$12.8M
Q1 24
$11.4M
Operating Margin
NECB
NECB
XLO
XLO
Q4 25
59.0%
-86.5%
Q3 25
61.6%
-10.1%
Q2 25
59.5%
-177.7%
Q1 25
57.4%
-472.7%
Q4 24
57.0%
Q3 24
63.6%
Q2 24
65.6%
Q1 24
62.7%
Net Margin
NECB
NECB
XLO
XLO
Q4 25
40.9%
75.7%
Q3 25
44.0%
-85.4%
Q2 25
43.1%
-196.0%
Q1 25
41.4%
-452.7%
Q4 24
40.1%
Q3 24
45.9%
Q2 24
47.5%
Q1 24
44.5%
EPS (diluted)
NECB
NECB
XLO
XLO
Q4 25
$0.78
$-3.74
Q3 25
$0.87
$-0.11
Q2 25
$0.82
$-0.16
Q1 25
$0.78
$-0.18
Q4 24
$0.74
Q3 24
$0.95
Q2 24
$0.97
Q1 24
$0.86

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
NECB
NECB
XLO
XLO
Cash + ST InvestmentsLiquidity on hand
$81.2M
$137.5M
Total DebtLower is stronger
$70.0M
Stockholders' EquityBook value
$351.7M
$35.3M
Total Assets
$2.1B
$154.7M
Debt / EquityLower = less leverage
0.20×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
NECB
NECB
XLO
XLO
Q4 25
$81.2M
$137.5M
Q3 25
$64.3M
$103.8M
Q2 25
$59.4M
$121.6M
Q1 25
$89.5M
$89.1M
Q4 24
$78.3M
Q3 24
$97.8M
Q2 24
$113.9M
Q1 24
$107.4M
Total Debt
NECB
NECB
XLO
XLO
Q4 25
$70.0M
Q3 25
$170.0M
Q2 25
$135.0M
Q1 25
Q4 24
Q3 24
$7.0M
Q2 24
$47.0M
Q1 24
$47.0M
Stockholders' Equity
NECB
NECB
XLO
XLO
Q4 25
$351.7M
$35.3M
Q3 25
$344.0M
$-8.1M
Q2 25
$336.7M
$7.1M
Q1 25
$327.2M
$10.7M
Q4 24
$318.3M
Q3 24
$309.6M
Q2 24
$300.0M
Q1 24
$288.9M
Total Assets
NECB
NECB
XLO
XLO
Q4 25
$2.1B
$154.7M
Q3 25
$2.1B
$133.7M
Q2 25
$2.0B
$133.8M
Q1 25
$1.9B
$103.7M
Q4 24
$2.0B
Q3 24
$2.0B
Q2 24
$1.9B
Q1 24
$1.9B
Debt / Equity
NECB
NECB
XLO
XLO
Q4 25
0.20×
Q3 25
0.49×
Q2 25
0.40×
Q1 25
Q4 24
Q3 24
0.02×
Q2 24
0.16×
Q1 24
0.16×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
NECB
NECB
XLO
XLO
Operating Cash FlowLast quarter
$52.6M
$-2.0M
Free Cash FlowOCF − Capex
$50.8M
$-2.1M
FCF MarginFCF / Revenue
192.3%
-15.3%
Capex IntensityCapex / Revenue
6.6%
0.7%
Cash ConversionOCF / Net Profit
4.86×
-0.19×
TTM Free Cash FlowTrailing 4 quarters
$89.9M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
NECB
NECB
XLO
XLO
Q4 25
$52.6M
$-2.0M
Q3 25
$14.1M
$-17.5M
Q2 25
$15.6M
$-14.5M
Q1 25
$10.9M
$29.0M
Q4 24
$48.7M
Q3 24
$14.4M
Q2 24
$11.1M
Q1 24
$12.9M
Free Cash Flow
NECB
NECB
XLO
XLO
Q4 25
$50.8M
$-2.1M
Q3 25
$13.6M
Q2 25
$14.9M
$-14.9M
Q1 25
$10.6M
$29.0M
Q4 24
$48.2M
Q3 24
$14.2M
Q2 24
$11.0M
Q1 24
$12.8M
FCF Margin
NECB
NECB
XLO
XLO
Q4 25
192.3%
-15.3%
Q3 25
50.5%
Q2 25
57.3%
-184.0%
Q1 25
41.4%
988.3%
Q4 24
189.3%
Q3 24
51.5%
Q2 24
40.8%
Q1 24
50.3%
Capex Intensity
NECB
NECB
XLO
XLO
Q4 25
6.6%
0.7%
Q3 25
1.6%
0.0%
Q2 25
2.9%
5.0%
Q1 25
1.5%
0.8%
Q4 24
2.0%
Q3 24
0.6%
Q2 24
0.5%
Q1 24
0.3%
Cash Conversion
NECB
NECB
XLO
XLO
Q4 25
4.86×
-0.19×
Q3 25
1.18×
Q2 25
1.40×
Q1 25
1.04×
Q4 24
4.77×
Q3 24
1.14×
Q2 24
0.87×
Q1 24
1.13×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons